Sex differences in mortality after percutaneous coronary intervention: a contemporary nationwide registry and prospective cohort analysis Authors: Kittipong Pinyosamosorn, Songsak Kiatchoosakun, Sasiporn Sitthisorn, Suwat Kongdumrongkiat, Monsan Lekcharoenwong, Chirasak Sirithunyanont, Bancha Sookananchai, Tanin Simtharakaew, Ammarin Thakkinstian, Nakarin Sansanayudh Published: 2025 ABSTRACT AbstractBackgroundDespite advancements in medical care, coronary artery disease (CAD) remains a leading cause of death. Previous studies have indicated a higher mortality rate for women compared to men following percutaneous coronary intervention (PCI). While both sexes share common risk factors, the magnitude of their impact may differ, and specific sex-related factors contribute to observed disparities. Although attempts have been made to reduce this gap, data concerning medical care and risk factors related to mortality remain limited. This study aims to assess the in-hospital mortality rate following PCI and to investigate sex-specific differences in associated risk factors.MethodsWe utilized a comprehensive national PCI registry comprising 19,701 patients. The patient cohort was stratified by sex. In-hospital mortality rates were reported, and risk factors related to mortality were analyzed using multivariable models.ResultsWomen exhibited a higher in-hospital mortality rate (3.5%) compared to men (2.3%). They were also more significantly affected by specific risk factors that increased mortality exclusively in women: chronic kidney disease (CKD) [odds ratio (OR) 2.73, 95% confidence interval (CI): 1.90–3.93, P<0.001], cerebrovascular disease (OR 2.43, 95% CI: 1.43–4.12, P=0.001), and cardiogenic shock (CS) at the time of PCI (OR 5.6, 95% CI: 3.85–8.15, P<0.001). Furthermore, several factors demonstrated a greater association with mortality in women compared to men. Women undergoing emergency PCI exhibited a higher odds ratio (OR 14.01, 95% CI: 8.03–24.43, P<0.001) than men (OR 3.77, 95% CI: 2.19–6.50, P<0.001). Similar trends were observed for urgent PCI (OR 5.58, 95% CI: 3.08–10.09, P<0.001 vs. OR 2.74, 95% CI: 1.64–4.58, P<0.001) and new required dialysis (OR 7.10, 95% CI: 2.84–17.77, P<0.001 vs. OR 3.28, 95% CI: 1.83–5.86, P<0.001).ConclusionsWomen undergoing PCI had significantly higher in-hospital and one-year mortality rates than men. Key risk factors for increased mortality in women include a history of stroke, CS, and CKD. While emergency PCI, dialysis initiation, arrhythmias, and procedure failure affect both sexes, their impact was more pronounced in women. Improving prognosis requires increased attention to women’s specific needs and enhanced awareness of appropriate peri-procedure care.Keywords: Percutaneous coronary intervention (PCI), in-hospital mortality, sex differences, risk factors Highlight box Key findings • Women had a higher in-hospital mortality rate (3.5%) compared to men (2.3%) after percutaneous coronary intervention (PCI). Specific health conditions, including chronic kidney disease (CKD), a history of stroke, and cardiogenic shock (CS), were found to be significantly greater risk factors for mortality exclusively in women. What is known and what is new? • Existing research indicates that coronary artery disease (CAD) is a leading cause of death globally, and women often show higher unadjusted mortality rates after PCI compared to men. This disparity is linked to women typically being older and having more comorbidities, as well as biological and sociocultural factors. • The study confirms significantly higher in-hospital and 1-year mortality rates for women after PCI, utilizing a comprehensive national registry. Crucially, it identifies that specific complications (emergency procedures, new dialysis, arrhythmias, procedure failure) have a more pronounced negative impact on women. The study pinpoints specific risk factors—a history of stroke, CS, and CKD—as key contributors to this increased female mortality risk. What is the implication, and what should change now? • Closing the gender gap in PCI outcomes requires a targeted, multi-faceted approach. We must accelerate care by minimizing the time to first medical contact and aggressively managing cardiovascular risk factors. Crucially, optimizing procedural outcomes demands enhanced clinical attention for high-risk women—including those with CKD, a history of stroke, or CS—and prioritizing advanced imaging technologies like intravascular ultrasound or optical coherence tomography to ensure superior procedural success. Introduction Despite advances in cardiovascular care, coronary artery disease (CAD) remains the leading cause of death worldwide. Previous research has demonstrated increased mortality rates among women compared to men following percutaneous coronary intervention (PCI) (1-5), though some registries show no significant difference (6,7). While both genders share common risk factors for mortality following PCI, such as hypertension (HT), dyslipidemia (DLP), chronic kidney disease (CKD), and smoking (8,9), the magnitude of their impact may differ. Specific gender-related factors contribute to the observed sex-based mortality disparity. Females undergoing PCI are often older and present with a greater burden of comorbidities compared to males. Additional contributing risk factors include biological sex differences, such as smaller arterial diameters that may lead to technical difficulties during procedures, and sociocultural factors, such as the presentation of atypical symptoms leading to treatment delays (10-21). Previous clinical practices have attempted to reduce this sex-based mortality disparity, but data on the specific medical care and risk factors related to in-hospital mortality have been limited. Therefore, this study aimed to identify the risk factors associated with in-hospital mortality in men and women within the Thai PCI registry to ultimately enhance patient healthcare services, optimize clinical outcomes, and improve the utilization of healthcare resources. We present this article in accordance with the STROBE reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-25-97/rc). Methods The Cardiac Intervention Association of Thailand (CIAT) initiated the Thai PCI Registry, a prospective, multicenter study that enrolled 19,701 patients between November 2015 and May 2018. All catheterization laboratories in Thailand were invited to participate, with 39 hospitals across the country ultimately contributing data voluntarily. The detailed methodology for the registry has been published previously (22). The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The Registry was approved by the Central Research Ethics Committee of Thailand (COA-CREC 006/2018). Further details are available on the CIAT website. Research nurses at local sites systematically recorded all data—including patient characteristics, procedural specifics, equipment and medication use, complications, and in-hospital outcomes—using a specifically-developed electronic case record form (eCRF). The definitions used in this study were consistent with previous reports (22). Urgent PCI was defined as a semi-urgent procedure requiring a short waiting time for execution, performed within 72 hours, depending on the patient’s condition and medical facility readiness. Emergency PCI was defined as a procedure that must proceed as soon as possible. Arrhythmias requiring treatment were defined as those necessitating additional medication or intervention, such as tachyarrhythmias (e.g., ventricular fibrillation or ventricular tachycardia requiring defibrillation) or bradyarrhythmias (e.g., heart block) requiring a temporary pacemaker. Procedure complications were defined as the presence of a residual dissection, perforation, no-reflow phenomenon, major side branch occlusion, acute stent thrombosis, catheter thrombosis, device loss, dislodgement, or rupture. Procedural failure was defined as a treatment result with a residual stenosis of greater than or equal to 50% after plain old balloon angioplasty (POBA), or greater than or equal to 20% after stenting. Statistical analysis Continuous variables were presented as mean ± standard deviation (SD) or median and interquartile range (IQR), as appropriate. Categorical variables were described as a frequency and percentage (n, %). The age distribution was divided into four groups: below 45 years (premenopausal), 45 to 59 years (before retirement), 60 to 80 years, and over 80 years. Differences between the sex groups for continuous variables were computed using the t-test or the Mann-Whitney U test, where appropriate. Categorical variables were compared using the χ2 test or Fisher’s exact test. A simple logistic regression model was constructed to assess risk factors for in-hospital mortality, stratified by sex. Risk factors with a P value of< 0.1 in this step were simultaneously considered in a multivariate model. Only significant variables, as suggested by a likelihood ratio (LR) test were retained in the final multivariate logistic regression model. The odds ratio (OR) and 95% confidence intervals (CI) were calculated. Statistical significance was defined as a two-sided P value of <0.05. All analyses were stratified by sex and performed using STATA version 17.0 (Stata Corp., College Station, TX, USA). Study endpoints The primary endpoint of this study was in-hospital mortality, defined as death from any cause during hospitalization after a PCI. The main cause of patient death was categorized into one of the following options: cardiac (heart disease, sudden death of unknown cause), neurologic, renal, vascular, infection and pulmonary (22). Results This study utilized a nationwide registry to examine sex differences in outcomes among 19,701 patients who underwent percutaneous coronary intervention (PCI) (22). The analysis revealed that women undergoing PCI were older than men (mean age: 67.3±11.3 vs. 62.8±11.6 years, P<0.001). This age disparity was further highlighted by the higher proportion of octogenarians among female patients (13.5%) compared to male patients (7.1%) (Table 1). Table 1Baseline characteristics of patientsFactorsTotal (n=19,701)GenderP valueFemale (n=6,083)Male (n=13,618)Age, years64.2±11.767.3±11.362.8±11.6<0.001 >801,799 (9.1)824 (13.5)975 (7.2)<0.001 60–8010,825 (54.9)3,707 (60.9)7,118 (52.3) 45–596,007 (30.5)1,377 (22.6)4,630 (34.0) <451,070 (5.4)175 (2.9)895 (6.6)Refer case10,747 (54.6)3,234 (53.2)7,513 (55.2)0.009Health coverage scheme<0.001 Universal coverage12,534 (63.6)4,138 (68.0)8,396 (61.7) Social security service1,329 (6.7)245 (4.0)1,084 (8.0) Others601 (3.1)171 (2.8)430 (3.2) Government service/state enterprise5,237 (26.6)1,529 (25.1)3,708 (27.2)BMI, kg/m224.3±4.224.3±4.524.3±4.00.74BMI Under weight1,294 (6.6)448 (7.4)846 (6.2)<0.001 Normal 6,523 (33.1)2,123 (34.9)4,400 (32.3) Over weight 4,298 (21.8)1,150 (18.9)3,148 (23.1) Obesity7,584 (38.5)2,362 (38.8)5,222 (38.4)Admission SBP, mmHg 137.3±26.7140.9±28.5135.7±25.8<0.001Admission HR, bpm76.1±16.778.2±17.075.1±16.4<0.001Smoking status<0.001 Current smoker4,608 (23.4)286 (4.7)4,322 (31.7) Ex-smoker6,306 (32.0)410 (6.7)5,896 (43.3) Never8,787 (44.6)5,387 (88.6)3,400 (25.0)Hypertension13,286 (67.4)4,732 (77.8)8,554 (62.8)<0.001Dyslipidemia12,857 (65.3)4,285 (70.4)8,572 (62.9)<0.001Cerebrovascular disease1,117 (5.7)347 (5.7)770 (5.7)0.89Family history of premature CAD1,835 (9.3)545 (9.0)1,290 (9.5)0.25Peripheral arterial disease341 (1.7)116 (1.9)225 (1.7)0.21Prior MI4,575 (23.2)1,401 (23.0)3,174 (23.3)0.67Known CAD6,677 (33.9)2,049 (33.7)4,628 (34.0)0.68Prior heart failure2,686 (13.6)1,070 (17.6)1,616 (11.9)<0.001Prior valve surgery/procedure92 (0.5)38 (0.6)54 (0.4)0.03CKD6,391 (32.4)2,578 (42.4)3,813 (28.0)<0.001Prior CABG309 (1.6)101 (1.7)208 (1.5)0.49Diabetes mellitus8,703 (44.2)3,386 (55.7)5,317 (39.0)<0.001CAD presentation<0.001 STEMI5,479 (27.8)1,444 (23.7)4,035 (29.6) NSTEMI/unstable angina5,976 (30.3)2,125 (34.9)3,851 (28.3) Stable CAD8,246 (41.9)2,514 (41.3)5,732 (42.1)Disease vessel<0.001 SVD5,202 (26.4)1,567 (25.8)3,635 (26.7) DVD5,675 (28.8)1,645 (27.0)4,030 (29.6) TVD6,447 (32.7)2,101 (34.5)4,346 (31.9) Left main2,377 (12.1)770 (12.7)1,607 (11.8)PCI status<0.001 Emergency4,476 (22.7)1,207 (19.8)3,269 (24.0) Urgent3,090 (15.7)1,034 (17.0)2,056 (15.1) Elective12,135 (61.6)3,842 (63.2)8,293 (60.9)Number of treated lesions1.2±0.51.3±0.51.2±0.50.67Initial access site<0.001 Radial only8,681 (44.1)2,465 (40.5)6,216 (45.6) Brachial only24 (0.1)4 (0.1)20 (0.1) Femoral only10,615 (53.9)3,506 (57.6)7,109 (52.2) Combination367 (1.9)102 (1.7)265 (1.9) Others14 (0.1)6 (0.1)8 (0.1)More than one attempt1,205 (6.1)466 (7.7)739 (5.4)<0.001Cross-over578 (2.9)221 (3.6)357 (2.6)<0.001Total volume of contrast, mL100.0 (70.0–130.0)100.0 (70.0–130.0)100.0 (70.0–138.0)>0.99Procedural medications Fondaparinux102 (0.5)29 (0.5)73 (0.5)0.59 Low molecular weight heparin2,351 (11.9)795 (13.1)1,556 (11.4)0.001 Unfractionated heparin17,956 (91.1)5,529 (90.9)12,427 (91.3)0.41 Aspirin19,539 (99.2)6,029 (99.1)13,510 (99.2)0.50 GP IIb/IIIa inhibitors1,176 (6.0)281 (4.7)895 (6.6)<0.001 Clopidogrel18,283 (92.8)5,695 (93.6)12,588 (92.4)0.003 Ticlopidine68 (0.3)20 (0.3)48 (0.4)0.79 Prasugrel339 (1.7)60 (1.0)279 (2.0)<0.001 Ticagrelor1,594 (8.1)456 (7.5)1,138 (8.4)0.04Cardiogenic shock at start of PCI1,523 (7.7)465 (7.6)1,058 (7.8)0.76IABP667 (3.4)206 (3.4)461 (3.4)0.98Number of guiding catheters used1.1±0.41.1±0.41.1±0.40.29Number of guide wire used1.0 (1.0–2.0)1.0 (1.0–2.0)1.0 (1.0–2.0)>0.99Number of balloons used2.0 (1.0–2.0)2.0 (1.0–3.0)2.0 (1.0–2.0)>0.99Number of stents used1.0 (1.0–2.0)1.0 (1.0–2.0)1.0 (1.0–2.0)>0.99Lesion complexity0.10 A830 (4.2)256 (4.2)574 (4.2) B12,918 (14.9)917 (15.2)2,001 (14.8) B23,645 (18.6)1,062 (17.6)2,583 (19.1) C12,196 (62.3)3,805 (63.0)8,391 (61.9)IVUS2,654 (13.5)830 (13.6)1,824 (13.4)0.63FFR381 (1.9)114 (1.9)267 (2.0)0.68OCT192 (1.0)73 (1.2)119 (0.9)0.03Rotablator425 (2.2)166 (2.7)259 (1.9)<0.001Length of stay, days2.0 (1.0–4.0)2.0 (1.0–4.0)2.0 (1.0–4.0)>0.99Treatment delay, h254.2 (16.7–1,935.6)306.7 (25.5–1,996.2)228.4 (14.6–1,908.1)0.001 Treatment delay for STEMI7.9 (4.3–19.3)9.0 (4.8–22.5)7.4 (4.1–18.4)<0.001 Treatment delay for NSTEMI210.4 (65.0–1,331.6)212.1 (69.4–1,355.8)210.4 (63.3–1,312.3)0.92 Treatment delay stable CAD1,716.5 (585–2,990)1,735.7 (639.3–2,938.6)1,706.3 (558.6–3,010.8)0.62Data are presented as n (%), mean ± standard deviation or median (interquartile range). BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; DVD, double vessel disease; FFR, fractional flow reserve; GP, glycoprotein; HR, heart rate; IABP, intra-aortic balloon pump; IVUS, intravascular ultrasonography; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Baseline characteristics of patients Data are presented as n (%), mean ± standard deviation or median (interquartile range). BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; DVD, double vessel disease; FFR, fractional flow reserve; GP, glycoprotein; HR, heart rate; IABP, intra-aortic balloon pump; IVUS, intravascular ultrasonography; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Baseline characteristics showed women had a higher prevalence of traditional risk factors. Common cardiovascular risk factors—such as HT, DLP, type 2 diabetes mellitus (T2DM), being underweight, prior heart failure, prior valvular surgery, and CKD—were more prevalent in women. Men, conversely, were more likely to smoke, present with ST-elevation myocardial infarction (STEMI), and undergo emergency PCI. Other risk factors, including cerebrovascular accident (CVA), peripheral artery disease (PAD), prior coronary artery bypass grafting (CABG), family history of premature CAD, prior MI, and known CAD, did not differ between the two groups. Regarding health coverage schemes, more women were using universal coverage (68%) than men (61.7%). STEMI and emergency PCI were more frequent in men, whereas non-ST-elevation myocardial infarction (NSTEMI) and stable CAD occur more frequently in women. Additionally, the time to PCI for STEMI was delayed in women, averaging 9.0 hours compared to 7.4 hours in men (Table 1). Regarding anatomical coronary vessels, women exhibited a higher prevalence of left main (LM) and triple-vessel disease (TVD) compared with men, though anatomical complexity in types B and C did not differ significantly between the sexes. Procedurally, women showed higher prevalence in femoral access, multiple attempts, crossover procedures, and rotablator use, while men more frequently utilized radial access; pharmacologically, men were more commonly administered glycoprotein (GP) IIb/IIIa inhibitors, ticagrelor, and prasugrel. Women experienced higher in-hospital (3.5% vs. 2.3%; P<0.001) and 1-year mortality rates (13.4% vs. 9.1%; P<0.001) and tended towards higher procedural complications (5.7% vs. 5.0%; P=0.04), with bleeding, endotracheal tube (ET-tube) use, and heart failure more prevalent in women (Table 2). Table 2Intra and post procedure events between genderFactorsTotal (n=19,701)GenderP valueFemale (n=6,083)Male (n=13,618)Death in hospital531 (2.7)212 (3.5)319 (2.3)<0.001Death 1 year2,061 (10.5)816 (13.4)1,245 (9.1)<0.001Procedural failure921 (4.7)276 (4.5)645 (4.7)0.54Procedure complications1,021 (5.2)345 (5.7)676 (5.0)0.04Vascular complications required treatment63 (0.3)22 (0.4)41 (0.3)0.49AV fistula13 (0.1)3 (0.0)10 (0.1)0.54Pseudoaneurysm13 (0.1)6 (0.1)7 (0.1)0.06Tamponade33 (0.2)14 (0.2)19 (0.1)0.15New requirement for dialysis103 (0.5)34 (0.6)69 (0.5)0.64Infection79 (0.4)26 (0.4)53 (0.4)0.69Bleeding complications958 (4.9)352 (5.8)606 (4.4)<0.001Blood transfusion195 (1.0)113 (1.9)82 (0.6)<0.001Bleeding complications or blood transfusion1,070 (5.4)417 (6.9)653 (4.8)<0.001Arrhythmia that required treatment0.82 Arrhythmia with treatment671 (3.4)208 (3.4)463 (3.4) Arrhythmia without treatment251 (1.3)82 (1.3)169 (1.2) No arrhythmia18,779 (95.3)5,793 (95.2)12,986 (95.4)ET intubation818 (4.2)288 (4.7)530 (3.9)0.006Temporary pacemaker201 (1.0)63 (1.0)138 (1.0)0.89Cardioversion/defibrillation265 (1.3)83 (1.4)182 (1.3)0.87Myocardial infarction1,187 (6.0)366 (6.0)821 (6.0)0.97CVA/stroke75 (0.4)28 (0.5)47 (0.3)0.23Heart failure2,381 (12.1)842 (13.8)1,539 (11.3)<0.001Cardiogenic shock1,504 (7.6)497 (8.2)1,007 (7.4)0.058CABG at discharge60 (0.3)20 (0.3)40 (0.3)0.68Data are presented as n (%). AV, arteriovenous; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; ET, endotracheal tube. Intra and post procedure events between gender Data are presented as n (%). AV, arteriovenous; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; ET, endotracheal tube. Factors associated with in-hospital mortality also varied by sex (Table 3). The in-hospital death rate increased with age for both sexes. Regarding the underlying diseases, a history of CVA (OR 2.53, P<0.001) was primarily associated with increased mortality in women. In men, factors associated with mortality included current smoking (OR 1.66, P<0.001), a history of prior valve surgery or procedure (OR 3.36, P=0.02), LM CAD (OR 3.30, P<0.001), vascular complications requiring intervention (OR 5.87, P<0.001), and bleeding complications (OR 2.65, P<0.001). Procedural failure and the use of GP IIb/IIIa inhibitors impacted mortality in both groups, but they had a more pronounced effect in women (procedural failure: OR 3.93, 95% CI: 2.63–5.88, P<0.001 among women vs. OR 2.65, 95% CI: 1.86–3.78, P<0.001 among men; GP IIb/IIIa inhibitors: OR 4.36, 95% CI: 2.95–6.42, P<0.001 among women vs. OR 2.85, 95% CI: 2.10–3.86, P<0.001 among men). Emergency PCI was also an impact factor for both groups, with a greater impact in women (OR 29.87, 95% CI: 18.46–48.32, P<0.001 among women vs. OR 17.86, 95% CI: 12.48–25.54, P<0.001 among men). Table 3Factors associated with in-hospital mortality stratified by gender: a univariate analysisFactorsFemaleMaleDeath (N=212)Alive (N=5,871)OR (95% CI)P valueDeath (N=319)Alive (N=13,299)OR (95% CI)P valueAge, years73.5±11.767.1±11.21.06 (1.04–1.07)<0.00168.7±12.362.6±11.61.05 (1.04–1.06)<0.001 >8068 (8.3)756 (91.7)3.85 (1.38–10.68)0.0160 (6.2)915 (93.8)6.46 (3.18–13.09)<0.001 60–80117 (3.2)3,590 (96.8)1.39 (0.51–3.82)0.52180 (2.5)6,938 (97.5)2.55 (1.30–5.01)0.006 45–5923 (1.7)1,354 (98.3)0.73 (0.25–2.12)0.5670 (1.5)4,560 (98.5)1.51 (0.75–3.04)0.25 <454 (2.3)171 (97.7)19 (1.0)886 (99.0)1Refer case137 (4.2)3,097 (95.8)1.64 (1.23–2.18)0.001204 (2.7)7,309 (97.3)1.45 (1.15–1.83)0.002Health coverage scheme Universal coverage151 (3.6)3,987 (96.4)1.05 (0.77–1.45)0.74220 (2.6)8,176 (97.4)1.34 (1.03–1.75)0.03 Social security service4 (1.6)241 (98.4)0.46 (0.17–1.29)0.1420 (1.8)1,064 (98.2)0.94 (0.57–1.54)0.80 Others4 (2.3)167 (97.7)0.67 (0.24–1.87)0.446 (1.4)424 (98.6)0.70 (0.30–1.63)0.41 Government service/state enterprise53 (3.5)1,476 (96.5)173 (2.0)3,635 (98.0)1BMI Obesity64 (2.7)2,298 (97.3)0.64 (0.46–0.88)0.00797 (1.9)5,125 (98.1)0.66 (0.51–0.87)0.003 Over weight33 (2.9)1,117 (97.1)0.68 (0.45–1.01)0.05878 (2.5)3,070 (97.5)0.89 (0.67–1.19)0.43 Under weight26 (5.8)422 (94.2)1.41 (0.90–2.21)0.1420 (2.4)826 (97.6)0.85 (0.53–1.37)0.50 Normal89 (4.2)2,034 (95.8)1122 (2.8)4,278 (97.2)1Admission SBP, mmHg117.0±34.2141.7±27.90.97 (0.96–0.97)<0.001117.2±36.2136.1±25.30.97 (0.97–0.98)<0.001Admission HR, bpm86.9±25.177.9±16.51.03 (1.02–1.03)<0.00187.6±27.374.8±16.01.04 (1.03–1.04)<0.001Smoking status Current smoker10 (3.5)276 (96.5)0.99 (0.52–1.88)0.97154 (3.6)4,168 (96.4)1.66 (1.25–2.20)<0.001 Ex-smoker11 (2.7)399 (97.3)0.75 (0.40–1.39)0.3691 (1.5)5,805 (98.5)0.70 (0.52–0.96)0.03 Never191 (3.5)5,196 (96.5)174 (2.2)3,326 (97.8)1Hypertension157 (3.3)4,575 (96.7)0.81 (0.59–1.11)0.18175 (2.0)8,379 (98.0)0.71 (0.57–0.89)0.003Dyslipidemia119 (2.8)4,166 (97.2)0.52 (0.40–0.69)<0.001136 (1.6)8,436 (98.4)0.43 (0.34–0.54)<0.001Cerebrovascular disease27 (7.8)320 (92.2)2.53 (1.66–3.85)<0.00123 (3.0)747 (97.0)1.31 (0.85–2.01)0.23Family history of premature CAD12 (2.2)533 (97.8)0.60 (0.33–1.08)0.0911 (0.9)1,279 (99.1)0.34 (0.18–0.61)<0.001Peripheral arterial disease8 (6.9)108 (93.1)2.09 (1.01–4.35)0.04817 (7.6)208 (92.4)3.54 (2.13–5.88)<0.001Prior MI34 (2.4)1,367 (97.6)0.63 (0.43–0.91)0.0243 (1.4)3,131 (98.6)0.51 (0.37–0.70)<0.001Known CAD28 (1.4)2,021 (98.6)0.29 (0.19–0.43)<0.00150 (1.1)4,578 (98.9)0.35 (0.26–0.48)<0.001Prior heart failure49 (4.6)1,021 (95.4)1.43 (1.03–1.98)0.0367 (4.1)1,549 (95.9)2.02 (1.53–2.65)<0.001Prior valve surgery/procedure2 (5.3)36 (94.7)1.54 (0.37–6.45)0.554 (7.4)50 (92.6)3.36 (1.21–9.37)0.02CKD157 (6.1)2,421 (93.9)4.07 (2.98–5.55)<0.001191 (5.0)3,622 (95.0)3.99 (3.18–5.00)<0.001Prior CABG3 (3.0)98 (97.0)0.85 (0.27–2.69)0.786 (2.9)202 (97.1)1.24 (0.55–2.82)0.60Diabetes mellitus138 (4.1)3,248 (95.9)1.51 (1.13–2.01)0.005166 (3.1)5,151 (96.9)1.72 (1.37–2.14)<0.001CAD presentation STEMI152 (10.5)1,292 (89.5)18.37 (10.93–30.88)<0.001214 (5.3)3,821 (94.7)21.35 (12.63–36.09)<0.001 NSTEMI/unstable angina44 (2.1)2,081 (97.9)3.30 (1.86–5.87)<0.00190 (2.3)3,761 (97.7)9.12 (5.27–15.78)<0.001 Stable CAD16 (0.6)2,498 (99.4)115 (0.3)5,717 (99.7)1Disease vessel Left main44 (5.7)726 (94.3)1.38 (0.93–2.04)0.1191 (5.7)1,516 (94.3)3.30 (2.38–4.56)<0.001 TVD51 (2.4)2,050 (97.6)0.57 (0.39–0.82)0.00386 (2.0)4,260 (98.0)1.11 (0.80–1.53)0.53 DVD51 (3.1)1,594 (96.9)0.73 (0.50–1.06)0.0977 (1.9)3,953 (98.1)1.07 (0.77–1.49)0.69 SVD66 (4.2)1,501 (95.8)165 (1.8)3,570 (98.2)1PCI status Emergency156 (12.9)1,051 (87.1)29.87 (18.46–48.32)<0.001230 (7.0)3,039 (93.0)17.86 (12.48–25.54)<0.001 Urgent37 (3.6)997 (96.4)7.47 (4.28–13.04)<0.00154 (2.6)2,002 (97.4)6.36 (4.15–9.76)<0.001 Elective19 (0.5)3,823 (99.5)135 (0.4)8,258 (99.6)1Cardiogenic shock at start of PCI126 (27.1)339 (72.9)23.91 (17.8–32.12)<0.001202 (19.1)856 (80.9)25.10 (19.78–31.84)<0.001Total volume of contrast, mL100.0 (20.0–420.0)100.0 (10.0–600.0)1.002 (0.999–1.004)0.11100.0 (80.0–140.0)100.0 (70.0–135.0)1.000 (0.998–1.002)0.77IABP81 (39.3)125 (60.7)28.22 (20.31–39.20)<0.001153 (33.2)308 (66.8)39.12 (30.54–50.11)<0.001Initial access site Brachial only and other1 (10.0)9 (90.0)7.71 (0.95–62.54)0.0560 (0.0)28 (100.0)–– Femoral only168 (4.8)3,338 (95.2)3.49 (2.42–5.05)<0.001240 (3.4)6,869 (96.6)3.41 (2.58–4.51)<0.001 Combination8 (7.8)94 (92.2)5.91 (2.67–13.09)<0.00116 (6.0)249 (94.0)6.28 (3.57–11.02)<0.001 Radial only35 (1.4)2,430 (98.6)163 (1.0)6,153 (99.0)1Manual compression183 (4.7)3,674 (95.3)3.77 (2.54–5.60)<0.001265 (3.2)7,909 (96.8)3.34 (2.49–4.49)<0.001Closure device8 (2.4)329 (97.6)0.66 (0.32–1.35)0.265 (0.9)556 (99.1)0.36 (0.15–0.89)0.03Low molecular weight heparin30 (3.8)765 (96.2)1.10 (0.74–1.63)0.6334 (2.2)1,522 (97.8)0.92 (0.64–1.32)0.66Unfractionated heparin191 (3.5)5,338 (96.5)0.91 (0.57–1.44)0.68283 (2.3)12,144 (97.7)0.75 (0.53–1.06)0.11Aspirin208 (3.4)5,821 (96.6)0.45 (0.16–1.25)0.12316 (2.3)13,194 (97.7)0.84 (0.26–2.66)0.76GP IIb/IIIa inhibitors34 (12.1)247 (87.9)4.36 (2.95–6.42)<0.00152 (5.8)843 (94.2)2.85 (2.10–3.86)<0.001Clopidogrel203 (3.6)5,492 (96.4)1.56 (0.79–3.06)0.20289 (2.3)12,299 (97.7)0.78 (0.53–1.15)0.21Ticlopidine1 (5.0)19 (95.0)1.46 (0.19–10.96)0.712 (4.2)46 (95.8)1.82 (0.44–7.52)0.41Prasugrel1 (1.7)59 (98.3)0.47 (0.06–3.39)0.452 (0.7)277 (99.3)0.30 (0.07–1.2)0.09Ticagrelor16 (3.5)440 (96.5)1.01 (0.60–1.69)0.9829 (2.5)1,109 (97.5)1.10 (0.75–1.62)0.63New requirement for dialysis21 (61.8)13 (38.2)49.54 (24.44–100.42)<0.00129 (42.0)40 (58.0)33.15 (20.27–54.21)<0.001Vascular complications required treatment1 (4.5)21 (95.5)1.32 (0.18–9.86)0.795 (12.2)36 (87.8)5.87 (2.29–15.05)<0.001Infection4 (15.4)22 (84.6)5.11 (1.75–14.97)0.0038 (15.1)45 (84.9)7.58 (3.54–16.21)<0.001Bleeding complications15 (4.3)337 (95.7)1.25 (0.73–2.14)0.4134 (5.6)572 (94.4)2.65 (1.84–3.83)<0.001Blood transfusion12 (10.6)101 (89.4)3.43 (1.85–6.34)<0.00114 (17.1)68 (82.9)8.93 (4.97–16.05)<0.001Bleeding complications or blood transfusion21 (5.0)396 (95.0)1.52 (0.96–2.41)0.0839 (6.0)614 (94.0)2.88 (2.04–4.06)<0.001Arrhythmia that required treatment Arrhythmia with treatment60 (28.8)148 (71.2)17.12 (12.12–24.18)<0.00196 (20.7)367 (79.3)16.89 (12.96–22.02)<0.001 Arrhythmia without treatment18 (22.0)64 (78.0)11.88 (6.85–20.59)<0.00125 (14.8)144 (85.2)11.21 (7.17–17.54)<0.001 No arrhythmia134 (2.3)5,659 (97.7)1198 (1.5)12,788 (98.5)1ET intubation113 (39.2)175 (60.8)37.15 (27.28–50.60)<0.001186 (35.1)344 (64.9)52.67 (41.14–67.42)<0.001Temporary pacemaker17 (27.0)46 (73.0)11.04 (6.22–19.61)<0.00130 (21.7)108 (78.3)12.68 (8.32–19.32)<0.001Cardioversion/defibrillation41 (49.4)42 (50.6)33.28 (21.08–52.52)<0.00166 (36.3)116 (63.7)29.65 (21.38–41.11)<0.001Myocardial infarction41 (11.2)325 (88.8)4.09 (2.86–5.86)<0.00162 (7.6)759 (92.4)3.99 (2.99–5.31)<0.001Heart failure162 (19.2)680 (80.8)24.73 (17.83–34.3)<0.001244 (15.9)1,295 (84.1)30.16 (23.14–39.31)<0.001Procedural failure31 (11.2)245 (88.8)3.93 (2.63–5.88)<0.00136 (5.6)609 (94.4)2.65 (1.86–3.78)<0.001Procedure complications40 (11.6)305 (88.4)4.24 (2.95–6.10)<0.00163 (9.3)613 (90.7)5.09 (3.82–6.79)<0.001Lesion complexity C141 (3.7)3,664 (96.3)1.19 (0.58–2.46)0.63219 (2.6)8,172 (97.4)1.68 (0.86–3.29)0.13 B240 (3.8)1,022 (96.2)1.21 (0.56–2.62)0.6254 (2.1)2,529 (97.9)1.34 (0.66–2.73)0.42 B121 (2.3)896 (97.7)0.73 (0.32–1.66)0.4536 (1.8)1,965 (98.2)1.15 (0.55–2.40)0.71 A8 (3.1)248 (96.9)19 (1.6)565 (98.4)1Treatment delay, h11.6 (4.8–38.0)369.9 (29.3–2,066.9)0.998 (0.997–0.999)<0.0018.2 (4.4–28.4)260.2 (15.7–1965.8)0.998 (0.997–0.999)<0.001Data are presented as n (%), mean ± standard deviation or median (interquartile range) unless otherwise indicated. BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; DVD, double vessel disease; ET, endotracheal tube; GP, glycoprotein; IABP, intra-aortic balloon pump; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Factors associated with in-hospital mortality stratified by gender: a univariate analysis Data are presented as n (%), mean ± standard deviation or median (interquartile range) unless otherwise indicated. BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; DVD, double vessel disease; ET, endotracheal tube; GP, glycoprotein; IABP, intra-aortic balloon pump; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. After adjusting for baseline variables (as shown in Table 4 and Figure 1), both femoral access and procedural complications were identified as statistically significant mortality risks for both sexes. Several risk factors were significant for both genders but demonstrated a greater impact on women compared with men: emergency PCI presentation (OR 14.01, 95% CI: 8.03–24.43, P<0.001 among women vs. OR 3.77, 95% CI: 2.19–6.50; P<0.001 among men), urgency (OR 5.58, 95% CI: 3.08–10.09, P<0.001 vs. OR 2.74, 95% CI: 1.64–4.58, P<0.001), new required dialysis (OR 7.10, 95% CI: 2.84–17.77, P<0.001 vs. OR 3.28, 95% CI: 1.83–5.86, P<0.001), arrhythmia requiring treatment (OR 3.66, 95% CI: 2.33–5.75, P<0.001 vs. OR 3.09, 95% CI: 2.22–4.29, P<0.001), and procedure failure (OR 3.41, 95% CI: 1.95–5.96, P<0.001 vs. OR 1.85, 95% CI: 1.16–2.95, P=0.01). Mortality risk factors also exhibited sex-specific differences. In men, the identified risk factors included HT, heart failure, PAD, STEMI, NSTEMI, prior valvular surgery, and LM CAD. Conversely, in women, the key mortality risk factors were a history of CVA (OR 2.43, 95% CI: 1.43–4.12; P=0.001), cardiogenic shock (CS) at the start of PCI (OR 5.61, 95% CI: 3.85–8.15, P<0.001), and CKD (OR 2.73, 95% CI: 1.90–3.93, P<0.001). Table 4Factors associated with in-hospital all caused mortality stratified by gender: a multivariate analysisFactorsFemaleMaleOR (95% CI)P valueOR (95% CI)P valueRefer case0.49 (0.34–0.71)<0.0010.51 (0.38–0.68)<0.001Diabetes mellitus1.04 (0.74–1.47)0.821.17 (0.89–1.53)0.26Peripheral arterial disease1.67 (0.69–4.06)0.265.23 (2.73–10.01)<0.001PCI status Emergency14.01 (8.03–24.43)<0.0013.77 (2.19–6.50)<0.001 Urgent5.58 (3.08–10.09)<0.0012.74 (1.64–4.58)<0.001 Elective11Arrhythmia that required treatment Arrhythmia with treatment3.66 (2.33–5.75)<0.0013.09 (2.22–4.29)<0.001 Arrhythmia without treatment2.30 (1.16–4.59)0.022.40 (1.40–4.11)0.001 No arrhythmia11New requirement for dialysis7.10 (2.84–17.77)<0.0013.28 (1.83–5.86)<0.001Procedure complications2.39 (1.50–3.83)<0.0012.03 (1.40–2.92)<0.001Procedural failure3.41 (1.95–5.96)<0.0011.85 (1.16–2.95)0.01Initial access site Brachial only and other20.54 (2.28–185.37)0.007–– Femoral only1.84 (1.21–2.81)0.0042.27 (1.65–3.10)<0.001 Combination3.20 (1.18–8.70)0.023.05 (1.53–6.06)0.001 Radial only11Cardiogenic shock at start of PCI5.61 (3.85–8.15)<0.001Cerebrovascular disease2.43 (1.43–4.12)0.001CKD2.73 (1.90–3.93)<0.001Heart failure6.97 (5.10–9.53)<0.001Admission HR, bpm1.02 (1.01–1.02)<0.001Admission SBP, mmHg0.99 (0.98–0.99)<0.001Dyslipidemia0.56 (0.42–0.75)<0.001CAD presentation STEMI3.20 (1.58–6.48)0.001 NSTEMI3.79 (2.01–7.14)<0.001 Stable CAD1Disease vessel Left main2.66 (1.79–3.96)<0.001 TVD1.34 (0.92–1.95)0.13 DVD1.20 (0.83–1.75)0.33 SVD1Family history of premature CAD0.38 (0.20–0.76)0.006Prior valve surgery/procedure4.98 (1.39–17.84)0.01Hypertension1.38 (1.03–1.85)0.03CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; DVD, double vessel disease; HR, hazard ratio; NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Factors associated with in-hospital all caused mortality stratified by gender: a multivariate analysis CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; DVD, double vessel disease; HR, hazard ratio; NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Factors associated with in-hospital mortality stratified by gender: a multivariate analysis. CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; DVD, double vessel disease; HR, hazard ratio; NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; SVD, single vessel disease; TVD, triple vessel disease. Discussion The principal finding was a higher in-hospital mortality rate for women undergoing PCI compared to men (3.5% vs. 2.3%, P<0.001). In women, in-hospital mortality was significantly associated with a history of CVA, the presence of CS at the start of the procedure, and CKD. The 1-year follow-up mortality rate was also significantly higher in women than in men (13.4% vs. 9.1%, P<0.001). These findings are consistent with previous studies, which reported that women with acute myocardial infarction had both lower rates of invasive procedure uptake and a higher in-hospital mortality rate than men (1,3,4,23). According to the 2014 Global Gender Gap Report by the World Economic Forum, Thailand ranked 61 out of 142 countries, indicating persistent gender disparity in economic participation, educational attainment, health, and political empowerment (24). This disparity may also extend to health outcomes, as evidenced by CAD data from the United States, where the estimated prevalence is higher in men (60%) than in women (40%) (25,26). Similarly, the Thai PCI registry reported a prevalence of PCI that was twice as high in men as in women. However, significant data gaps remain regarding the overall prevalence of CAD within Thailand. Prior research indicates that women typically develop clinical manifestations of CAD approximately 10–20 years later than men and are more likely to receive undertreatment (27-29). Consistent with this finding, a Thai PCI registry study reported a two-fold higher prevalence of CAD among octogenarian women compared to men (13.5% vs. 7.1%). This delayed presentation of ischemic heart disease in women was also associated with a higher prevalence of cardiovascular risk factors (for example, T2DM, CKD, PAD, and history of CVA) and appeared to have a more significant impact on mortality risk compared to men (30-35). Women with CKD experience an attenuation or loss of their inherent survival advantage over men. This disparity is attributed to a complex interaction of hormonal changes, resulting in a greater excess mortality burden in women. Biological factors contributing to this trend include the loss of estrogen’s protective effect. In the general population, estrogen confers a protective effect against cardiovascular disease. In the context of CKD, the production and balance of sex hormones are altered, which may eliminate this cardioprotective effect in women, particularly post-menopause or in advanced stages of CKD. Additionally, women with CKD exhibit a distinct vulnerability to the impact of cardiovascular disease. Some studies suggest that when these women develop cardiovascular complications, the impact is more severe, leading to disproportionately higher mortality rates compared to men with similar conditions. There is also a differential impact of risk factors, as high albuminuria appears to have a greater effect on cardiovascular risk in women than in men (36,37). Furthermore, CKD negatively impacts the prognosis of CAD. Patients with CKD exhibit a higher prevalence of severe and complex coronary lesions, such as multivessel and LM artery disease (38-40). CKD patients presenting with STEMI frequently experience hemodynamic instability, which is associated with increased in-hospital mortality (41). In this study, CKD was more prevalent and significantly impacted mortality risk, specifically in women (OR 2.73, 95% CI: 1.90–3.93, P<0.001). The need for newly initiated dialysis was identified as a serious complication associated with mortality risk in both women (OR 7.10, 95% CI: 2.84–17.77, P<0.001) and men (OR 3.28, 95% CI: 1.83–5.86, P<0.001); however, this association was more pronounced in women. Various studies demonstrate significant sex-based differences in the severity and etiology of CVA. The severity of CVA is reportedly higher in women than in men, with distinct underlying causes observed. Men typically exhibit large artery atherosclerosis, whereas women present with more cardiac embolic strokes, a difference attributed to a higher incidence of atrial fibrillation in women (42,43). Increased cardiovascular and cerebrovascular mortality in women is linked to biological mechanisms such as myocardial infarction with non-obstructive coronary arteries (MINOCA), hormonal changes after menopause, and female-specific risk factors related to pregnancy. These factors lead to worse outcomes because MINOCA is often missed on standard angiography, while hormonal shifts accelerate vascular aging and HT, and pregnancy complications are underrecognized risk factors for future events. In this study, a history of CVA was significantly associated with increased mortality in women (OR 2.43, 95% CI: 1.43–4.12, P=0.001). Additionally, a later clinical presentation and a higher burden of conventional cardiovascular risk factors were associated with worse outcomes for women. In patients undergoing PCI, CS at the time of intervention was associated with the most severe clinical presentation. Prior research has shown that women have a higher mortality in CS cases, possibly because they were less likely to receive percutaneous left ventricular assist devices (LVADs) but more likely to receive inotropes (44). Other research has found that women have a higher mortality rate during the first eight days after intra-aortic balloon pump (IABP) insertion, with older age, more comorbidities, and mechanical complications identified as independent risk factors (45,46). In the present study, CS present at the start of PCI was a risk factor exclusively in women (OR 5.61, 95% CI: 3.85–8.15, P<0.001). Multiple factors contribute to worse outcomes in women. Clinically, women were older and had a higher burden of comorbidities compared to men. Furthermore, atypical symptoms that can delay diagnosis and treatment, combined with smaller vessel anatomy that impedes device insertion and increases the risk of procedural failure, contribute to a more severe presentation. Contributing factors, such as difficulties with vascular access and post-PCI complications, were more common in women and contributed to higher mortality rates. Previous studies had identified several risk factors for vascular complications that were more prevalent in women. These included a smaller radial artery diameter at the access site, which could increase bleeding risk, particularly when switching from a radial to a femoral approach due to difficulties such as an artery being too small, spastic or requiring a larger catheter. Comorbidities such as being underweight and being elderly were also associated with complex coronary lesions, leading to technical difficulties during procedures. Additionally, women’s smaller-caliber coronary arteries and a higher prevalence of plaque erosion may increase the risk of restenosis and stent thrombosis, both of which have been shown to contribute to suboptimal PCI outcomes in women (18-20,46,47). In our study, women experienced a slightly higher prevalence of both vascular complications (0.4% vs. 0.3% in men) and procedural complications (5.7% vs. 5.0% in men); however, these differences were not statistically significant when compared with men Furthermore, several risk factors associated with vascular complications were more prominent in women, including a higher rate of multiple arterial access attempts (7.7% vs. 5.4%) and a greater prevalence of being underweight (7.4% vs. 6.2%). Women also presented with an older age and more complex coronary lesions (Class C: 63.0% vs. 61.9%) at the time of the event. Other mortality factors identified were delayed time to treatment, under-recognition of heart disease, and differences in clinical presentation that often led to less aggressive treatment strategies for women. Delayed initiation of critical medication and revascularization procedures was also more common in women, and emergent PCI was a more significant mortality factor for women than for men (10,11,21,48). The influence of factors potentially associated with female sex on clinical outcomes may involve variables that are currently unknown. This could lead to an apparent association with adverse outcomes, even though other causative factors (e.g., hormonal status, endothelial dysfunction, or microcirculation disorders) may be involved. In the future, an intensive focus on modifiable cardiovascular risk factors, time to first medical contact (21,48), and awareness of peri-procedural care may lead to the use of advanced devices and techniques [e.g., using drug-eluting stents (DES), evaluating vessel size and morphology by intravascular ultrasound (IVUS) or optical coherence tomography (OCT)] in women, ultimately reducing their mortality rate (6,46). Limitations This study has several limitations. Primarily, reliance on registry data can introduce selection bias (e.g., incomplete recording of patient demographics or procedural details) and result in a lack of data on long-term outcomes. Secondly, the study failed to sufficiently analyze female-specific risk factors for CAD, including pregnancy-related complications such as gestational diabetes, pregnancy-induced hypertension, and preeclampsia (49); emotional stress associated with stress cardiomyopathy (50,51); and autoimmune processes like systemic lupus erythematosus and rheumatoid arthritis, which can induce atherosclerosis (52). Conclusions Women undergoing PCI experienced significantly higher in-hospital and one-year mortality rates compared with men. Key risk factors contributing to this increased mortality in women include a history of stroke, CS, and CKD. While emergency or urgent PCI procedures, the need for dialysis initiation, the presence of arrhythmias, and procedure failure negatively affect both sexes, their impact appears to be more pronounced in women. Improving patient prognosis requires increased clinical attention to women’s specific needs and enhanced awareness of appropriate peri-procedure care to mitigate these disparities. Supplementary The article’s supplementary files as Acknowledgments The authors thank the Health Systems Research Institute (HSRI) and DMU for their support and for assistance with data analyses. The authors also thank Mr. Bryan Roderick Hamman for his assistance with the English-language presentation of the manuscript. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The Registry was approved by the Central Research Ethics Committee of Thailand (COA-CREC 006/2018). Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://atm.amegroups.com/article/view/10.21037/atm-25-97/rc Funding: This study was funded by the Health System Research Institute of the Ministry of Public Health in Thailand. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-25-97/coif). The authors have no conflicts of interest to declare. References Available at https://atm.amegroups.com/article/view/10.21037/atm-25-97/prf Supplementary Materials The article’s supplementary files as